Availability of Systemic Antifungals in Africa: A Comparative Study between North Africa and West Africa
1 Service of Parasitology-Mycology, Faculty of Medicine, Pharmacy and Odontology, Cheikh Anta Diop University, BO 3005, Dakar, Senegal
2 Laboratory of Parasitology and Mycology, Aristide Le Dantec University Hospital, BO 3001, Dakar, Senegal
3 Centre International de Recherche et de Formation en Génomique Appliquée, et de Surveillance Sanitaire (CIGASS), Cheikh Anta Diop University of Dakar, BO 16477, Dakar, Senegal
4 Department of Parasitology-Mycology-Animal Biology-Zoology, UFR Sciences pharmaceutiques et biologiques, Felix Houphouët-Boigny University, BO V34, Abidjan, Côte d’Ivoire
5 Laboratory of Parasitology-Mycology, National institute of Public Health, BO V34, Abidjan, Côte d’Ivoire
6 Laboratory of the « Mère et Enfant » Hospital Center, BO 40028, Nouakchott, Mauritania
7 UFR 2S, Assane Seck University of Ziguinchor, BO 523 Ziguinchor, Senegal
* Corresponding author: ; Phone: +221 77 437 04 61
* Author to whom correspondence should be addressed.
Received: 31 Dec 2022 / Revised: 3 Apr 2023 / Accepted: 15 May 2023 / Published: 13 Jun 2023
Abstract
Introduction. Due to the lack of systemic antifungals (SAs), many invasive fungal infections (IFIs) do not yet benefit from effective treatment in Africa. Yet, fungi are a major threat to human health. This study aimed to assess the availability of SAs and compare this availability between West Africa (WA) and North Africa (NA). Materials and methods. The information processed was obtained during the same period between February and June 2021 in Senegal, Mauritania, and Côte d’Ivoire as well as in Morocco and Tunisia. In WA, data were received from wholesale drug suppliers and private pharmacies while in NA, the data were those available on the websites of the pharmacy and drug directorates. Results. All classes of SAs were available. However, this availability was not uniform depending on location, whether in WA or NA. Fluconazole and itraconazole were the only SA available in WA. In NA, all classes of SAs have been found, particularly in Morocco, while flucytosine was the only molecule absent in Tunisia. Conclusion. NA is ahead of WA as regards the burden of IFIs both diagnostically and in the availability of SAs. Studies on the epidemiology of IFIs in Africa, particularly in WA, are limited. The partial data available highlight that IFIs are not negligible, though these may be underestimated. Thus, a network based on the directory of African pharmacy and drug directorates must be set up and run in collaboration with the national laboratory directorates for the harmonization of procedures in order to reduce morbidity and mortality related to IFIs.
Keywords: Systemic Antifungals; West Africa; North Africa; Fungal Infections
OPEN ACCESS
This is an open access article distributed under the Creative Commons Attribution
License which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. (CC BY 4.0).
CITE
Diongue, K.; Miezan, A.-S.; Sy, O.; Diop, A.; Diallo, M.A.; Seck, M.C.; Ndiaye, M.; Badiane, A.S.; Ndiaye, D. Availability of Systemic Antifungals in Africa: A Comparative Study between North Africa and West Africa. ajpme 2023, 1, 4.
Diongue K, Miezan A-S, Sy O, Diop A, Diallo MA, Seck MC, Ndiaye M, Badiane AS, Ndiaye D. Availability of Systemic Antifungals in Africa: A Comparative Study between North Africa and West Africa. African Journal of Parasitology, Mycology and Entomology. 2023; 1(1):4.
Diongue, Khadim; Miezan, Assohoun J-S.; Sy, Ousmane; Diop, Abdoulaye; Diallo, Mamadou A.; Seck, Mame C.; Ndiaye, Mouhamadou; Badiane, Aida S.; Ndiaye, Daouda. 2023. "Availability of Systemic Antifungals in Africa: A Comparative Study between North Africa and West Africa." ajpme 1, no. 1: 4.
Not implemented
SHARE
